177lu-psma-617
177lu-psma-617 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 6, 2026: “Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer”.
See all 1 papers on 177lu-psma-617
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 6 trials, none about aging.
“increases in maximal CH VAF correlated with the number of 177Lu-PSMA-617 cycles received (+2.9% per cycle; P = 0.002).”
None of its findings points the other way.
- 1 lab in 1 country
- 6 trials, none about aging
- Funders: BC Cancer Foundation and 7 more
- 3 of 6 trials sponsored by its developers
- Human trial1
Studies in people
1 study gave 177lu-psma-617 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases clonal hematopoiesis of indeterminate potential62% vs. 40%, OR 3.2, P = 0.03 up: Increases clonal expansion70.9% vs. 29.5%, P = 7.5 × 10-5 up: Increases variant allele frequency+2.9% per cycle, P = 0.002 | Randomized trial | 107 peopleMenMCRPC | Clinical cancer research : an official journal of the American Association for Cancer Research, Feb 6, 2026 |
What did studies of 177lu-psma-617 find?
4Studies of 177lu-psma-617 measured 4 outcomes, among them variant allele frequency, clonal expansion and PPM1D.
Variant allele frequency
upin humans1
1 study
Variant allele frequency
upin humans1
177lu-psma-617 increases variant allele frequency in humans (mCRPC) (+2.9% per cycle, P = 0.002).
“increases in maximal CH VAF correlated with the number of 177Lu-PSMA-617 cycles received (+2.9% per cycle; P = 0.002).”
Human trialmCRPC
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research
Clonal expansion
upin humans1
1 study
Clonal expansion
upin humans1
177lu-psma-617 increases clonal expansion in humans (mCRPC) (70.9% vs. 29.5%, P = 7.5 × 10-5).
“CH clones expanded more frequently and to a greater magnitude with 177Lu-PSMA-617 (proportion expanding, 70.9% vs. 29.5%; P = 7.5 × 10-5)”
Human trialmCRPCn = 107
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research
PPM1D
upin humans1OR 5.4
1 study
PPM1D
upin humans1OR 5.4
177lu-psma-617 increases PPM1D in humans (mCRPC) (OR 5.4).
“The DNA damage response gene PPM1D accounted for 42% (51/121) of 177Lu-PSMA-617-emergent mutations, with odds ratios of 3.2 for any treatment-emergent CH and 5.4 for PPM1D, relative to cabazitaxel.”
Human trialmCRPCn = 107
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research
Clonal hematopoiesis of indeterminate potential
upin humans1OR 3.2
1 study
Clonal hematopoiesis of indeterminate potential
upin humans1OR 3.2
177lu-psma-617 increases clonal hematopoiesis of indeterminate potential in humans (mCRPC) (62% vs. 40%, OR 3.2, P = 0.03).
“Treatment-emergent CH occurred more often after 177Lu-PSMA-617 than cabazitaxel [62% (37/60) vs. 40% (19/47); P = 0.03]”
Human trialmCRPCn = 107
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research
Who is developing 177lu-psma-617?
1 company: Novartis Pharmaceuticals.
- Companies
- Novartis PharmaceuticalsPhase 3prostatic neoplasm, metastatic castration-resistant prostate cancer
Trial sponsors
Novartis Pharmaceuticals Corporation
Company3 trialsPhase 31,620 people
University of California, San Francisco
1 trialPhase 130 people